Health
Deactivating gene could boost immunotherapy for head and neck cancer – Drug Target Review
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers were able to significantly slow the growth and spread of tumours in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. The study was conducted…
-
Noosa News18 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News16 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoBrisbane Broncos star Reece Walsh says punching friend in face ‘not a good look’
-
General14 hours agoDairy farmers devastated by floods across parts of New South Wales